Sun Pharmaceutical Industries Limited

Regd Office: Sun Pharma Advanced Research Centre, Tandalja, Vadodara-390020

Corporate Office : Acme Plaza, Andheri-Kurla Road, Andheri (E), Mumbai - 400059

Audited Financial Results for the year ended March 31, 2011

	Quarter ended		Year e
	31.03.11 Unaudited	31.03.10 Unaudited	**31.03.11 Audited**
Income			
Net Sales / Income from Operations	49,874	46,532	1,93,312
Other operating Income	31,357	20,425	1,17,158
Total Income	**81,231**	**66,957**	**3,10,470**
Expenditure			
(Increase) / Decrease in Stock in trade and work in progress	(3,401)	(1,119)	199
Consumption of Materials	21,216	19,946	71,826
Purchase of Traded Goods	3,953	4,051	17,668
Employees' Cost	7,042	5,529	26,109
Depreciation / Amortisation	1,583	2,019	6,423
Other Expenditure	17,466	15,215	62,544
Total Expenditure	**47,859**	**45,641**	**1,84,769**
Profit from Operations before Other Income, Interest & Tax	**33,372**	**21,316**	**1,25,701**
Other Income	1,625	3,528	7,108
Profit before Interest & Tax	**34,997**	**24,844**	**1,32,809**
Net Interest Income	3,892	2,044	12,593
Profit after Interest but before Tax	**38,889**	**26,888**	**1,45,402**
Tax Expense	1,611	1,284	7,022
Net Profit from ordinary activities after tax	**37,278**	**25,604**	**1,38,380**
Paid-up Equity Share Capital			
Equity Shares - Face Value ₹ 1 each (Previous periods ` 5 each)	10,356	10,356	10,356
Reserves excluding Revaluation Reserve			6,57,697
Earnings Per Share of ₹ 1 each - in ` (Basic & Diluted)	**3.6**	**2.5**	**13.4**
Public Shareholding			
No. of Equity Shares of ₹ 1 each (Previous periods ` 5 each)	**37,57,53,755**	7,51,50,451	**37,57,53,755**
Percentage of Shareholding	**36.28**	36.28	**36.28**
Promoters and Promoter Group Shareholding			
a) Pledged / Encumbered			
No. of Equity Shares of ₹ 1 each (Previous periods ` 5 each)	**23,34,500**	6,85,000	**23,34,500**
Percentage of Equity Shares (as a % of the total shareholding of promoters and promoter group)	**0.35**	0.52	**0.35**
Percentage of Equity Shares (as a % of the total share capital of the Company)	**0.23**	0.33	**0.23**
b) Non-encumbered			
No. of Equity Shares of ₹ 1 each (Previous periods ` 5 each)	**65,74,93,700**	13,12,80,940	**65,74,93,700**
Percentage of Equity Shares (as a % of the total shareholding of promoters and promoter group)	**99.65**	99.48	**99.65**
Percentage of Equity Shares (as a % of the total share capital of the Company)	**63.49**	63.39	**63.49**
Research & Development Expenses incurred (included above)	3,888	4,228	15,728

Notes :

1 Statement of Assets and Liabilities

Particulars	**As at 31.03.2011**		As at 31.
SHAREHOLDERS' FUNDS :			
(a) Capital	**10,356**		10,356
(b) Reserves and Surplus	**6,57,697**	**6,68,053**	5,61,442
LOAN FUNDS		**5,053**	
DEFERRED TAX LIABILITY (NET)		**12,851**	
TOTAL		**6,85,957**	
FIXED ASSETS		**1,02,245**	
INVESTMENTS		**3,60,142**	
CURRENT ASSETS, LOANS AND ADVANCES			
(a) Inventories	**61,826**		57,014
(b) Sundry Debtors	**54,262**		55,329
(c) Cash and Bank balances	**1,25,090**		8,887
(d) Other current assets	**1,837**		579
(e) Loans and Advances	**55,258**		36,613
	2,98,273		1,58,422
Less: Current Liabilities and Provisions			
(a) Liabilities	**31,393**		26,330
(b) Provisions	**43,310**		34,248
	74,703	**2,23,570**	60,578
TOTAL		**6,85,957**	

2 The above financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors a held on May 28, 2011.

3 Consequent to the approval of the members of the Company and upon requisite regulatory compliance, during the year, one equi each of the Company is sub-divided into five equity shares of ` 1 each fully paid up. The Earnings Per Share of ` 1 each has been res corresponding periods in accordance with Accounting Standard (AS-20) on 'Earnings Per Share" as notified under The Companie Standards) Rules, 2006.

4 The Board has recommended payment of dividend of ₹ 3.50 per equity share of ₹ 1 each for the year ended March 31, 2011 subject t members at ensuing Annual General Meeting.

5 Other Operating Income represents Share of Income from Partnership Firms.

6 The Company has only one reportable business segment namely 'Pharmaceuticals'.

7 Tax Expense includes Current Tax and Deferred Tax.

8 Status of investor complaints [in no.s] during the year, pursuant to clause 41 of the listing agreement : Opening [0]; Received [24]; Resolved [24]; Closing [0]

9 Figures for the previous period / year have been regrouped / reclassified, wherever considered necessary.

By order of the Board

Dilip S Shanghvi

Chairman and Managing

Mumbai, May 28, 2011

(₹ in Lakhs)

ended
31.03.10 Audited
1,80,785
67,766
2,48,551
(3,091)
70,926
13,704
21,215
6,947
52,931
1,62,632
85,919
(1,488)
84,431
10,485
94,916
5,051
89,865
10,356
5,61,442
8.7
7,51,50,451
36.28
6,85,000
0.52
0.33
13,12,80,940
99.48
63.39
14,408

.03.2010
5,71,798
2,949
11,533
5,86,280
83,267
4,05,169
97,844
5,86,280

t their meeting

ity share of ` 5
tated for all the
es (Accounting

approval of

g Director